Chemomab Therapeutics Ltd ADR (CMMB)

$1.50 -0.07 (-4.46%)
Market Cap 9.66M
Revenue (ttm) 0.00
Net Income (ttm) -13.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 32,200
Avg Vol 89,810
Day's Range N/A - N/A
Shares Out 6.16M
Stochastic %K 38%
Beta 0.56
Analysts Strong Sell
Price Target $17.50

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therape...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 77 331 0156
Address:
Building 7, Kiryat Atidim, Tel Aviv-Yafo, Israel
Snptrader
Snptrader Feb. 23 at 5:50 PM
$CMMB https://www.fda.gov/news-events/press-announcements/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases
0 · Reply
DLTT4489
DLTT4489 Feb. 23 at 5:24 PM
$CMMB geeeeeeet reeeeeady
0 · Reply
DLTT4489
DLTT4489 Feb. 23 at 5:23 PM
$CMMB wooooow, just woooow Volume is insane 😅😅😅😅
0 · Reply
DLTT4489
DLTT4489 Feb. 23 at 5:22 PM
$CMMB short this POS harder, all same team
0 · Reply
grumpygoose
grumpygoose Feb. 23 at 5:20 PM
$CMMB another week of nothing from this company
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 1:15 PM
$CMMB RSI: 51.06, MACD: -0.0701 Vol: 0.08, MA20: 1.59, MA50: 1.77 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DLTT4489
DLTT4489 Feb. 20 at 8:12 PM
$CMMB Look at the volume, it's insane 🤣🤣🤣🤣
0 · Reply
DLTT4489
DLTT4489 Feb. 20 at 6:24 PM
$CMMB get ready for next week
0 · Reply
DLTT4489
DLTT4489 Feb. 20 at 6:24 PM
$CMMB it's testing see it goes down towards $1.23.
0 · Reply
JoeShmoDoe
JoeShmoDoe Feb. 19 at 4:10 PM
$CMMB there are a minimum of 10 fake bullish accounts. No one ever buys this shit. Beware!
0 · Reply
Latest News on CMMB
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 8:00 AM EST - 6 days ago

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Dec 2, 2025, 8:00 AM EST - 2 months ago

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Nov 24, 2025, 8:00 AM EST - 3 months ago

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 20, 2025, 8:00 AM EST - 3 months ago

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Nov 6, 2025, 8:00 AM EST - 3 months ago

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 21, 2025, 8:00 AM EDT - 6 months ago

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 8:00 AM EDT - 6 months ago

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

Jun 30, 2025, 8:00 AM EDT - 8 months ago

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

Jun 11, 2025, 8:00 AM EDT - 9 months ago

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

Jun 3, 2025, 8:00 AM EDT - 9 months ago

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 10 months ago

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

May 5, 2025, 8:00 AM EDT - 10 months ago

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Apr 28, 2025, 8:00 AM EDT - 10 months ago

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Apr 21, 2025, 8:00 AM EDT - 11 months ago

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Chemomab Announces New Medical and Clinical Appointments

Apr 15, 2025, 8:00 AM EDT - 11 months ago

Chemomab Announces New Medical and Clinical Appointments

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Mar 27, 2025, 3:18 PM EDT - 11 months ago

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Mar 27, 2025, 8:30 AM EDT - 11 months ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Mar 6, 2025, 8:00 AM EST - 1 year ago

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Mar 3, 2025, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Feb 19, 2025, 7:00 AM EST - 1 year ago

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Nov 19, 2024, 7:00 AM EST - 1 year ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Jul 30, 2024, 9:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:38 AM EDT - 1 year ago

Chemomab Therapeutics Announces $10 Million Private Placement

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Jul 25, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 17, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 8, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

May 2, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Apr 18, 2024, 7:00 AM EDT - 2 years ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Mar 25, 2024, 7:06 AM EDT - 2 years ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Mar 5, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Feb 20, 2024, 7:00 AM EST - 2 years ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Feb 14, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Feb 5, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Jan 30, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Jan 3, 2024, 7:00 AM EST - 2 years ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Nov 16, 2023, 7:00 AM EST - 2 years ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Nov 15, 2023, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Nov 13, 2023, 8:00 AM EST - 2 years ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 8:00 AM EST - 2 years ago

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Nov 6, 2023, 4:15 PM EST - 2 years ago

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Oct 26, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Snptrader
Snptrader Feb. 23 at 5:50 PM
$CMMB https://www.fda.gov/news-events/press-announcements/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases
0 · Reply
DLTT4489
DLTT4489 Feb. 23 at 5:24 PM
$CMMB geeeeeeet reeeeeady
0 · Reply
DLTT4489
DLTT4489 Feb. 23 at 5:23 PM
$CMMB wooooow, just woooow Volume is insane 😅😅😅😅
0 · Reply
DLTT4489
DLTT4489 Feb. 23 at 5:22 PM
$CMMB short this POS harder, all same team
0 · Reply
grumpygoose
grumpygoose Feb. 23 at 5:20 PM
$CMMB another week of nothing from this company
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 1:15 PM
$CMMB RSI: 51.06, MACD: -0.0701 Vol: 0.08, MA20: 1.59, MA50: 1.77 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DLTT4489
DLTT4489 Feb. 20 at 8:12 PM
$CMMB Look at the volume, it's insane 🤣🤣🤣🤣
0 · Reply
DLTT4489
DLTT4489 Feb. 20 at 6:24 PM
$CMMB get ready for next week
0 · Reply
DLTT4489
DLTT4489 Feb. 20 at 6:24 PM
$CMMB it's testing see it goes down towards $1.23.
0 · Reply
JoeShmoDoe
JoeShmoDoe Feb. 19 at 4:10 PM
$CMMB there are a minimum of 10 fake bullish accounts. No one ever buys this shit. Beware!
0 · Reply
DLTT4489
DLTT4489 Feb. 19 at 3:33 PM
$CMMB countdown started
0 · Reply
JoeShmoDoe
JoeShmoDoe Feb. 19 at 3:26 PM
$CMMB 0.80 soon
0 · Reply
DLTT4489
DLTT4489 Feb. 18 at 4:34 PM
$CMMB $1.23 soon
0 · Reply
Snptrader
Snptrader Feb. 18 at 4:32 PM
$CMMB looks like citadel (103K shares) joined in as well as Adar1 Capital (80K) shares. 12/31/2025
1 · Reply
DLTT4489
DLTT4489 Feb. 18 at 1:17 PM
$CMMB good time to short it harder like yesterday. 🤑🤑
0 · Reply
ReversalKnight
ReversalKnight Feb. 18 at 9:38 AM
$CMMB Emerging-market exposure where policy risk overshadows fundamentals.
0 · Reply
cayman777
cayman777 Feb. 18 at 9:22 AM
$CMMB -From latest corporate slide deck -“Substantial strategic partner interest”. Peter Thiel 4.6% owner.
1 · Reply
Stock_Catcher
Stock_Catcher Feb. 18 at 2:23 AM
Wealthy Wednesday Watchlist Pt. 9 $VCIG $ALT $CMMB $FLY $BNAI Will Try to Find a 1000% Runner
1 · Reply
HMR1399
HMR1399 Feb. 18 at 12:53 AM
$CMMB partial fill, 1.60, hope rest fills 1.63
0 · Reply
dom3
dom3 Feb. 18 at 12:30 AM
$CMMB There will be resistance at 1.95. If that is broken...we will almost certainly head quickly to 2.25.
1 · Reply
dom3
dom3 Feb. 18 at 12:28 AM
$CMMB Wow; is this just an after hours move that we havn't seen in months or have we got news coming in the morning regarding the phase 111 trial. The volume is very strong.
0 · Reply
Zdxss1
Zdxss1 Feb. 18 at 12:13 AM
$CMMB If it closes near $2, it means there's a leak of information; if it reaches the official market closing price, it means there are children at play.
1 · Reply